Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Oncopeptalks – looking into 2025

January 22, 2025 – In the first Oncopeptalks of the year, David and Sofia takes a look at 2025 and discuss what the key goals and opportunities of the year could be.

Watch the video here

Sofia Heigis presented at Redeye Fight Cancer on January 22

January 22, 2025 – Sofia Heigis, CEO of Oncopeptides, presented Oncopeptides at the Redeye Fight Cancer event on January 22. Apart from individual company presentations the event includes Q&A-sessions with each company as well as panel discussions.

Read more and watch the presentation

Company news

Oncopeptalks – looking into 2025

January 22, 2025

In the first Oncopeptalks of the year, David and Sofia takes a look at 2025 and discuss what the key goals and opportunities of the year could be.

Read more

Oncopeptalks - 2024 in review

December 19, 2024

In the last Oncopeptalks episode of the year, David and Sofia summarizes the eventful 2024. They cover topics such as the future of Oncopeptides in the U.S., Spain and Italy, licensing agreements, financials and sales development.

Read more

Oncopeptides launches Italian website

December 9, 2024

As part of the company´s ongoing efforts to increase our visibility in Italy and strengthen relationships with the Italian community, Oncopeptides recently launched www.oncopeptides.it

Read more

Science news

Oncopeptides invited to present at ASH in December

November 20, 2024

Oncopeptides today announces that an evaluation of the activity of two peptide drug conjugates (PDCs) developed by Oncopeptides in relapsed or refractory Acute Myeloid Leukemia has been accepted as a poster and will be presented at the 66th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego, California between December 7-10.

Read more

First patient enters real-world data study in Germany

July 22, 2024

Oncopeptides recently announced entry of the first patient in a new study evaluating the real-world effectiveness and safety of Pepaxti in German patients.

Read more

Oncopeptides selects first candidate drug from its SPiKE platform

June 27, 2024

Oncopeptides recently announced that the first candidate drug based on the company´s unique platform for Small Polypeptide based innate Killer Engagers (SPiKE) has been selected.

Read more

Investor news

Sofia Heigis presented at Redeye Fight Cancer on January 22, 2025

January 22, 2025

Sofia Heigis, CEO of Oncopeptides, presented Oncopeptides at the Redeye Fight Cancer event on January 22. Apart from individual company presentations the event includes Q&A-sessions with each company as well as panel discussions.

Read more

Oncopeptides participated at Redeye Life Science event

December 4, 2024

Oncopeptides CEO Sofia Heigis recently participated at Redeye´s Technology and Life Science event in Stockholm.

Read more

Sofia Heigis presented at Stora Aktiedagarna

November 28, 2024

Oncopeptides' CEO Sofia Heigis presented the company at Stora Aktiedagarna organized by the organization Aktiespararna.

Read more

All Company news

All Science news

All Investor news

CEO Sofia Heigis - Oncopeptides AB

Released November 7, 2024

Oncopeptides publishes Q3 report 2024

Read report

Download

“Strong start in Spain offset by soft German market development”

CEO Sofia Heigis

 

See the Webcast

The webcast presentation in PDF

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Year-end report 2024 will be published February 27, 2025

Press release - November 27, 2024

Oncopeptides obtains reimbursement for Pepaxti in Italy

Read press release

Latest press releases

All press releases

Upcoming events

2025-01-28 - 2025-02-26

Silent period

Other

2025-02-27

Year-end Report 2024

Report

2025-04-08 - 2025-05-07

Silent period

Other

Full calendar
Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Oncopeptides via e-mail